Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2B 〉ACT Genomics

ACT Genomics

My Favorites
ACT Genomics is a global, science-driven biotech company enabling personalized treatment selection of cancer precision medicine with distinguished clinical cancer genomic profiling services.

To make the world a better place, ACT Genomics' philanthropic philosophy was brought alive to rewrite cancer patients' difficult times by its cutting-edge Next Generation Sequencing (NGS) technology since 2014. With the endeavor of leading experts in cancer biology, cancer genomics and bioinformatics, thousands of oncologists and patients in Asia-Pacific have been empowered to fight cancer at critical clinical moments.

Dedicated to transforming science into actionable solutions, ACT Genomics foresees enormous benefit in Asians' treatment if applying big data in Asian cancer genomics, so the company has been established high-quality Asian Genome Database ahead of time. Successfully bridging the needs among oncologists, biopharma and patients, ACT Genomics' experiences in Asia always lead forward-looking collaborations and strategic partnerships.

ACT Genomics is headquartered at Taiwan and operates in Singapore, Hong Kong, Japan and Shanghai, with one CAP certified NGS lab in Taiwan, and new labs in Japan and Hong Kong with nearly 200 staff. A joint venture ACTMed was formed with Canon Medical System and a co-promotion was established with AIA Hong Kong.
 
  • Hua Chien Chen, CEO & Cofounder

    Hua Chien Chen, CEO & Cofounder

    Earned Ph.D. in Biochemistry from NYMU with postdoctoral training in Molecular Biology at CWRU, US, and served in NHRI, TaiGen Biotech and CGU for biomarker discovery.
  • Shu Jen Chen, CSO & Cofounder

    Shu Jen Chen, CSO & Cofounder

    Earned Ph.D. in Biochemistry from VCU with postdoctoral training at BCM, US, she served in SUNY Buffalo, NHRI, TaiGen Biotech and CGU for biomarker discovery.
  • Joe Hsueh, COO & Cofounder

    Joe Hsueh, COO & Cofounder

    Earned MBA from FDU, US and B.A. in Microbiology from SCU in Taiwan, he served in NCKU, NHRI, Chengxin VC, TaiGen Biotech focusing on fundraising.
  • Victor Chan, CFO

    Victor Chan, CFO

    Earned MBA from CUHK, LLB from the University of London and BA from HKU, he served in financial related field, Standard Chartered Bank and biomedical start-ups focusing on investment.
  • Allen Lai, Senior VP/ Regional MD

    Allen Lai, Senior VP/ Regional MD

    Earned Ph.D. and MPA from Lee Kuan Yew School of Public Policy, NUS, M.Sc. from NTU and M.D. from CSMDU, TW, he served ISPOR, MHSW, IMS Health, ESSEC, NTUH focusing on consulting.
ACT Genomics is a global, science-driven biotech company enabling personalized treatment selection of cancer precision medicine with distinguished clinical cancer genomic profiling services.

To make the world a better place, ACT Genomics' philanthropic philosophy was brought alive to rewrite cancer patients' difficult times by its cutting-edge Next Generation Sequencing (NGS) technology since 2014. With the endeavor of leading experts in cancer biology, cancer genomics and bioinformatics, thousands of oncologists and patients in Asia-Pacific have been empowered to fight cancer at critical clinical moments.

Dedicated to transforming science into actionable solutions, ACT Genomics foresees enormous benefit in Asians' treatment if applying big data in Asian cancer genomics, so the company has been established high-quality Asian Genome Database ahead of time. Successfully bridging the needs among oncologists, biopharma and patients, ACT Genomics' experiences in Asia always lead forward-looking collaborations and strategic partnerships.

ACT Genomics is headquartered at Taiwan and operates in Singapore, Hong Kong, Japan and Shanghai, with one CAP certified NGS lab in Taiwan, and new labs in Japan and Hong Kong with nearly 200 staff. A joint venture ACTMed was formed with Canon Medical System and a co-promotion was established with AIA Hong Kong.
 
  Video